Rhenman & Partners Asset Management Ab Madrigal Pharmaceuticals, Inc. Transaction History
Rhenman & Partners Asset Management Ab
- $1.2 Billion
- Q3 2024
A detailed history of Rhenman & Partners Asset Management Ab transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 15,300 shares of MDGL stock, worth $4.8 Million. This represents 0.27% of its overall portfolio holdings.
Number of Shares
15,300
Previous 26,500
42.26%
Holding current value
$4.8 Million
Previous $7.42 Million
56.28%
% of portfolio
0.27%
Previous 0.73%
Shares
8 transactions
Others Institutions Holding MDGL
# of Institutions
297Shares Held
22MCall Options Held
819KPut Options Held
640K-
Janus Henderson Group PLC London, X02.48MShares$778 Million0.28% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.04MShares$641 Million29.57% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.03MShares$637 Million6.48% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$626 Million6.74% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$620 Million4.49% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.37B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...